- Email: [email protected]
Answers for CME examination
A n s w e r s for C M E e x a m i n a t i o n *
IdentificationNo. 886-106
June, 1986, issue of the JOURNAL OF THE AMERICAN ACADEMYOF DERMATOLOGY
Questions 1-33, Adams R M , Fisher AA: J AM ACAD DERMATOL 14:951-969, 1986. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18.
e (p 952, d (p 955, e (p 955, d (p 956, e (p 960, e (p 958, b (p 959, b (p 960, b (p 961, c (p964, a (p966, b (p967, a (p 968, e (p 965, d (p967, a (p967, c (p967, b (p967,
c 2, pa 3 - - p 953, c 1, pa 1) c 1, pa 5) c I, pa 5) c 1, pa 2; p 957, Ta VI) c 2, pa 2) c 2, pa 2) c 1, pa 2 - - p a 3) c 2, pa 3) e 1, pa 4) c2, pal) c 1, pa 1) c 1, p a 2 ) c 1, pa 5 - - e 2, pa 1) c 1, pa 3 - - c 2, pa 1) c 1, p a 3 ) c2, pa3) c 1, p a 5 ) c2, pal)
19. 20. 21. 22. 23. 24.
c a d c c c
25. b 26. a 27. a , b , c , d , e 28. None of the answers is correct 29. a , b , c , d , e 30. b , e 31. a , b , c , d , e 32. a , b , c , d , e 33. a, b, c, d, e
(p 957, c 2, pa 2) (p 957, c 2, pa 2) (p 957, c 2, pa 2) (p 957, c 1, pa 4) (p 957, c 1, pa 4 - - c 2, pa 1) (p 953, c 2, pa2; p 956, c 1, pa 1; p 960, c 1, pa 4) (p 960, c 1, pa 4) (p 960, c 1, pa 4) (p 957, c 2, pa 4 - - p 958, c 1, pa 1) (p 958, c 2, pa 3)
(p (p (p (p (p
958, 959, 958, 960, 960,
c 2, pa 3) c 2, pa 1) Ta IX; p 960, c 1, pa 2) c 2, pa 3) c 2, pa 3)
*p: page; e: column; pa: paragraph; Ta: table.
ABSTRACTS
Inhibition of the complement activation by an adrenal androgen, dehydroepiandrosterone
Natural killer cell activity in atopic dermatitis: A sequential study
Hidvegi T, Feher GK, Feher T, et al: Complement 1:201-206, 1984
Lever RS, Lesko MJ, Mackie RM, et al: Clin Allergy 15:479-486, 1985
Dehydroepiandrosterone (DEA) is an androgen natural in the adrenal gland that can inhibit the activation of both complement pathways. It blocks the classic path well and the alternative path only moderately. Other steriods that can achieve a block even better and more safely m~ght be developed. Keep watching. Philip C. Anderson, M.D.
The greater the activity of the atopic dermatitis the more suppressed was the NK (natural killer) function of lymphocytes over 12 months of this study. A good correlation of IgE in plasma with the clinical activity of the disease was noted also. Philip C. Anderson, M.D,
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose
Plasma exchange in the treatment of acute systemic lupus erythematosus without circulating immune complexes
Schafer-Korting M, Korting HC, Mutschler E: Eur J Clin Pharmacol 29:109-113, 1985
Passaleva A, Massai G, Emmi L, et al: Clin Exp Rheumatol 3:255-257, 1985
In blister fluid, griseofulvin increases up to about 6 hours after a single dose, while the plasma loads twice as fast. The half-value in clearing is 9 to 10 hours. About a day is required to gain equilibrium in all compartments. Ultramicrosize formulation may offer some advantages in using a smaller dose for equal amounts in tissue. Philip C. Andelwon, M.D.
Plasma exchange therapy (and plasmapheresis) for very severe and acute lupus erythematosus is becoming almost commonplace. Even if circulating immune complexes are not present, it works, at least to lower antinuclear antibodies. Much more experience is needed to decide the utility of it. Philip C. Anderson, M.D.
14
IdentificationNo. 886-106
June, 1986, issue of the JOURNAL OF THE AMERICAN ACADEMYOF DERMATOLOGY
Questions 1-33, Adams R M , Fisher AA: J AM ACAD DERMATOL 14:951-969, 1986. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18.
e (p 952, d (p 955, e (p 955, d (p 956, e (p 960, e (p 958, b (p 959, b (p 960, b (p 961, c (p964, a (p966, b (p967, a (p 968, e (p 965, d (p967, a (p967, c (p967, b (p967,
c 2, pa 3 - - p 953, c 1, pa 1) c 1, pa 5) c I, pa 5) c 1, pa 2; p 957, Ta VI) c 2, pa 2) c 2, pa 2) c 1, pa 2 - - p a 3) c 2, pa 3) e 1, pa 4) c2, pal) c 1, pa 1) c 1, p a 2 ) c 1, pa 5 - - e 2, pa 1) c 1, pa 3 - - c 2, pa 1) c 1, p a 3 ) c2, pa3) c 1, p a 5 ) c2, pal)
19. 20. 21. 22. 23. 24.
c a d c c c
25. b 26. a 27. a , b , c , d , e 28. None of the answers is correct 29. a , b , c , d , e 30. b , e 31. a , b , c , d , e 32. a , b , c , d , e 33. a, b, c, d, e
(p 957, c 2, pa 2) (p 957, c 2, pa 2) (p 957, c 2, pa 2) (p 957, c 1, pa 4) (p 957, c 1, pa 4 - - c 2, pa 1) (p 953, c 2, pa2; p 956, c 1, pa 1; p 960, c 1, pa 4) (p 960, c 1, pa 4) (p 960, c 1, pa 4) (p 957, c 2, pa 4 - - p 958, c 1, pa 1) (p 958, c 2, pa 3)
(p (p (p (p (p
958, 959, 958, 960, 960,
c 2, pa 3) c 2, pa 1) Ta IX; p 960, c 1, pa 2) c 2, pa 3) c 2, pa 3)
*p: page; e: column; pa: paragraph; Ta: table.
ABSTRACTS
Inhibition of the complement activation by an adrenal androgen, dehydroepiandrosterone
Natural killer cell activity in atopic dermatitis: A sequential study
Hidvegi T, Feher GK, Feher T, et al: Complement 1:201-206, 1984
Lever RS, Lesko MJ, Mackie RM, et al: Clin Allergy 15:479-486, 1985
Dehydroepiandrosterone (DEA) is an androgen natural in the adrenal gland that can inhibit the activation of both complement pathways. It blocks the classic path well and the alternative path only moderately. Other steriods that can achieve a block even better and more safely m~ght be developed. Keep watching. Philip C. Anderson, M.D.
The greater the activity of the atopic dermatitis the more suppressed was the NK (natural killer) function of lymphocytes over 12 months of this study. A good correlation of IgE in plasma with the clinical activity of the disease was noted also. Philip C. Anderson, M.D,
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose
Plasma exchange in the treatment of acute systemic lupus erythematosus without circulating immune complexes
Schafer-Korting M, Korting HC, Mutschler E: Eur J Clin Pharmacol 29:109-113, 1985
Passaleva A, Massai G, Emmi L, et al: Clin Exp Rheumatol 3:255-257, 1985
In blister fluid, griseofulvin increases up to about 6 hours after a single dose, while the plasma loads twice as fast. The half-value in clearing is 9 to 10 hours. About a day is required to gain equilibrium in all compartments. Ultramicrosize formulation may offer some advantages in using a smaller dose for equal amounts in tissue. Philip C. Andelwon, M.D.
Plasma exchange therapy (and plasmapheresis) for very severe and acute lupus erythematosus is becoming almost commonplace. Even if circulating immune complexes are not present, it works, at least to lower antinuclear antibodies. Much more experience is needed to decide the utility of it. Philip C. Anderson, M.D.
14